Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma

Sponsor
Jean M. Tersak, M.D.
Study ID
NCT00202930
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
2 Months - 18 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to evaluate the feasibility of giving four weekly doses of Rituximab (anti-CD20 antibody) in the treatment of children with refractory neuroblastoma associated opsoclonus-myoclonus. Patients must have continued symptoms of opsoclonus, myoclonus and or ataxia despite surgical resection and a minimum of one month of steroid therapy. Evaluations include clinical symptoms of opsoclonus-myoclonus and ataxia as well as detailed evaluation of learning and development.

Key Dates

Start date
Jul 31, 2005
Status verified
Jan 2021
Primary completion
Dec 31, 2008
Completion
Feb 5, 2009

Study Design

Enrollment
4 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Rituximab
    Single Arm

Primary Outcome Measure

Feasibility of Using 4 Weekly Rituximab Infusions [ Time Frame: 4 weeks ]

Related Studies